A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 16 May 2011 Primary endpoint, Montgomery Asberg Depression Rating Scale, has been met according to an Otsuka Pharmaceuticals media release.
    • 16 May 2011 Results have been presented at APA-2011 according to an Otsuka Pharmaceuticals media release; results were also reported in the media release.
    • 15 Jan 2010 Additional trial location (USA) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top